Baxter slides as investors brace for upcoming quarterly results amid lingering outlook and product-quality overhangs

Baxter International Inc. (BAX) is down 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks tied to risk reduction ahead of Baxter’s next earnings update, with investors still sensitive to the company’s weaker 2026 outlook and execution concerns. Ongoing product-quality and regulatory headline risk may also be contributing to negative sentiment into the print.

Details:

Baxter is scheduled to report first-quarter 2026 results before the U.S. market opens on April 30, 2026, a setup that often increases volatility as traders reposition ahead of fresh guidance and management commentary.

In its most recent full-year outlook discussion, Baxter laid out FY2026 adjusted EPS guidance and highlighted multiple business risks (including supply, quality, and restructuring/separation-related items), which has kept expectations fragile after prior disappointments.

The FDA has posted a Class 2 recall entry for Baxter OXIRIS (recall number Z-1226-2026), reinforcing that device-related updates remain a potential overhang for the shares.

This could also be amplified by broader de-risking in medtech ahead of earnings season, as investors favor companies with clearer near-term margin and growth visibility.

Sources:

Baxter Investor Relations, U.S. Food and Drug Administration (FDA), MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive BAX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BAX Hedge Fund Activity

We have seen 319 institutional investors add shares of $BAX stock to their portfolio, and 371 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 20,239,853 shares (+138.9%) to their portfolio in Q4 2025, for an estimated $386,783,590
AUTO-OWNERS INSURANCE CO removed 19,015,500 shares (-94.8%) from their portfolio in Q1 2026, for an estimated $319,460,400
PRICE T ROWE ASSOCIATES INC /MD/ removed 12,690,881 shares (-94.3%) from their portfolio in Q4 2025, for an estimated $242,522,735
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 9,027,190 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $172,509,600
BLACKROCK, INC. added 6,956,600 shares (+8.9%) to their portfolio in Q4 2025, for an estimated $132,940,626
UBS GROUP AG added 6,774,236 shares (+174.0%) to their portfolio in Q4 2025, for an estimated $129,455,649
PZENA INVESTMENT MANAGEMENT LLC removed 5,518,428 shares (-7.9%) from their portfolio in Q1 2026, for an estimated $92,709,590

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$BAX Congressional Stock Trading

Members of Congress have traded $BAX stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BAX stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$BAX Price Targets

Multiple analysts have issued price targets for $BAX recently. We have seen 5 analysts offer price targets for $BAX in the last 6 months, with a median target of $19.0.

Here are some recent targets:

Vijay Kumar from Evercore ISI Group set a target price of $22.0 on 04/06/2026
Joanne Wuensch from Citigroup set a target price of $19.0 on 03/11/2026
David Roman from Goldman Sachs set a target price of $17.0 on 02/17/2026
Matt Miksic from Barclays set a target price of $25.0 on 02/13/2026
Patrick Wood from Morgan Stanley set a target price of $15.0 on 12/02/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.